Search research articles
Contact Us
Filters
Showing results (141-150 of 174) with videos related to
Page
of 18
Sort By:
BMJ Open
|
April 13, 2023
Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial
Sandra Hayes, Andreas Obermair, Linda Mileshkin, et al.
The Journal of Clinical Investigation
|
March 6, 2019
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion
Christopher R McEvoy, Huiling Xu, Kortnye Smith, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial
Jonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 17, 2015
Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future
Satoru Sagae, Bradley J Monk, Eric Pujade-Lauraine, et al.
The Lancet. Oncology
|
July 12, 2016
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Journal for Immunotherapy of Cancer
|
January 31, 2023
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
Atara Posner, Tharani Sivakumaran, Andrew Pattison, et al.
Lancet (London, England)
|
August 3, 2024
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
Alwin Krämer, Tilmann Bochtler, Chantal Pauli, et al.
Theranostics
|
October 14, 2020
First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers
Andrew M Scott, Timothy Akhurst, Fook-Thean Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series
Emma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 23, 2021
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer
Paul A Cohen, Penelope M Webb, Madeleine King, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 174) with videos related to
Sort By:
Page
of 18
BMJ Open
|
April 13, 2023
Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial
Sandra Hayes, Andreas Obermair, Linda Mileshkin, et al.
The Journal of Clinical Investigation
|
March 6, 2019
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion
Christopher R McEvoy, Huiling Xu, Kortnye Smith, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial
Jonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 17, 2015
Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future
Satoru Sagae, Bradley J Monk, Eric Pujade-Lauraine, et al.
The Lancet. Oncology
|
July 12, 2016
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Journal for Immunotherapy of Cancer
|
January 31, 2023
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
Atara Posner, Tharani Sivakumaran, Andrew Pattison, et al.
Lancet (London, England)
|
August 3, 2024
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
Alwin Krämer, Tilmann Bochtler, Chantal Pauli, et al.
Theranostics
|
October 14, 2020
First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers
Andrew M Scott, Timothy Akhurst, Fook-Thean Lee, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series
Emma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 23, 2021
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer
Paul A Cohen, Penelope M Webb, Madeleine King, et al.
Page
of 18